Loading
NASDAQHealthcareBiotechnology
Latest quote
$2.03
+$0.02 · +1.00%
TuHURA Biosciences, Inc. is an immuno-oncology firm that has reached the critical Phase 3 registration stage of clinical development. The company is dedicated to pioneering innovative technologies designed to effectively combat the mechanisms by which cancers develop resistance to existing immunotherapy treatments. Its operations are based in Tampa, Florida.
Latest quote
$2.03
+$0.02 · +1.00%
After-hours
$2.03
$0.00 · 0.00%
Sep 10, 7:30 PM ET
Regular session · ET · Market data may be delayed.
TuHURA Biosciences, Inc. is an immuno-oncology firm that has reached the critical Phase 3 registration stage of clinical development. The company is dedicated to pioneering innovative technologies designed to effectively combat the mechanisms by which cancers develop resistance to existing immunotherapy treatments. Its operations are based in Tampa, Florida.
Day range
Current $2.03
52-week range
Current $2.03
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
25
Expensive
Sentiment
51
Mixed
Risk
57
Elevated Risk
Momentum
62
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
TuHURA Biosciences, Inc. is an immuno-oncology firm that has reached the critical Phase 3 registration stage of clinical development. The company is dedicated to pioneering innovative technologies designed to effectively combat the mechanisms by which cancers develop resistance to existing immunotherapy treatments. Its operations are based in Tampa, Florida.
Day range
Current $2.03
52-week range
Current $2.03
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | — | — | 55K USD | 60K USD | 60K USD |
| Gross profit | — | — | −55K USD | −60K USD | −60K USD |
| Research and development | 20.53M USD | 13.34M USD | 2.66M USD | 9.31M USD | 15.17M USD |
| Selling, general, and administrative | 7.58M USD | 3.87M USD | 5.73M USD | 5.43M USD | 7.45M USD |
| Operating expenses | 31.8M USD | 17.65M USD | 8.4M USD | 14.74M USD | 22.62M USD |
| Interest income | 136.23K USD | 361.63K USD | 89.67K USD | 57.35K USD | — |
| Interest expense | 625.28K USD | 4.14M USD | 18.69K USD | — | 629.29K USD |
| Depreciation and amortization | 71.27K USD | 116.71K USD | 55K USD | 60K USD | 60K USD |
| Operating income | −31.8M USD | −17.65M USD | −8.45M USD | −14.8M USD | −22.68M USD |
| Net income | −30.06M USD | −21.68M USD | −8.32M USD | −14.65M USD | −22.66M USD |
Company facts updated Sep 11, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Limited analyst sample: 3 ratings. Interpret the distribution with caution.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Oct 18, 2024 | 1:35 | — | — |
Stock split | Nov 14, 2022 | 1:50 | — | — |
Stock split | May 8, 2019 | 1:10 | — | — |
Stock split | May 23, 2016 | 1:4 | — | — |
Effective Oct 18, 2024
1:35
Effective Nov 14, 2022
1:50
Effective May 8, 2019
1:10
Effective May 23, 2016
1:4
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Extended Market ETFVXF
iShares Micro-Cap ETFIWCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
